1 / 33

Chronic Myelogenous Leukemia Diagnosis and Treatment

Chronic Myelogenous Leukemia Diagnosis and Treatment. Survival in Early CP CML. OS, PFS, and Probability of Remaining in CHR and EFS by ITT Analysis. Outcomes: ENESTnd and DASISION. DASISION: 4-Year Rates of MMR. ENESTnd: Cumulative Incidence of MMR.

charde-kaufman
Download Presentation

Chronic Myelogenous Leukemia Diagnosis and Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chronic Myelogenous LeukemiaDiagnosis and Treatment

  2. Survival in Early CP CML

  3. OS, PFS, and Probability of Remaining in CHR and EFS by ITT Analysis

  4. Outcomes: ENESTnd and DASISION

  5. DASISION: 4-Year Rates of MMR

  6. ENESTnd: Cumulative Incidence of MMR

  7. Progression to AP/BC on Study According to Sokal Risk Score

  8. DASISION: Transformation to AP/BP

  9. ENESTnd: Progression to AP/BC

  10. DASISION: OS and PFS

  11. ENESTnd: 5-Year EFS and PFS

  12. Compliance to Imatinib: ADAGIO Study

  13. Adherence and Molecular Response

  14. Cumulative Incidence of MMR According to BCR-ABL Level at 3 Months

  15. When to Consider Mutational Analysis

  16. Response and PFS With 2G-TKIsin Imatinib-Resistant CP-CML

  17. Newly Approved Agents for CML Patients Resistant or Intolerant to Prior Therapy

  18. Bosutinib Third Line: Best Cumulative Response

  19. PACE: Response to Ponatinib by Previous CP CML Therapy

  20. CCyR Rates After 2G-TKI Failure

  21. ENESTnd: Cardiovascular Events by 5 Years

  22. DASISION: Arterial Occlusive Events

  23. Take-Home Message

  24. IS TKI Therapy Forever?The STIM Trial

  25. Complete Molecular Remission After Discontinuation of Imatinib

  26. Abbreviations

  27. Abbreviations

  28. References

  29. References (cont)

  30. References (cont)

  31. References (cont)

  32. References (cont)

More Related